Table 1

Characteristics of human subjects and plasma samples

(A) Prediagnostic samples (Cardiovascular Health Study population)
	Cases (n=79)		Controls (n=79)
79 matched pairs	N	Per cent	N	Per cent
Sex
Male	44	55.7	44	55.7
Female	35	44.3	35	44.3
Age (years)
65–69	21	26.6	21	26.6
70–74	30	38	33	41.8
75–79	21	26.6	18	22.8
>80	7	8.9	7	8.9
Race
White	70	88.6	70	88.6
Black	9	11.4	9	11.4
Body mass index
Normal (19.0–24.9)	33	41.8	24	30.4
Overweight (25.0–29.9)	27	34.2	38	48.1
Obese (30.0–)	19	24.1	17	21.5
Cancer diagnosed after the blood draw
<2 years	67	84.8
>2, <3 years	12	15.2
Cancer sites
Proximal	25	31.6
Distal	42	53.2
Proximal and distal	2	2.2
Rectal	10	12.7

(B) Diagnostic samples (Early Detection Research Network study population)
	Adenomas (n=60)		Cancers (n=60)		Controls (n=60)
	n	Per cent	n	Per cent	n	Per cent
Sex
Male	29	48.3	34	56.7	16	26.7
Female	31	51.7	26	43.3	44	73.3
Age (years)
30–39	1	1.7	1	1.7	3	5
40–49	2	3.3	12	20	8	13.3
50–59	23	38.3	12	20	30	50
60–69	21	35	13	21.7	14	23.3
70–79	10	16.7	13	21.7	5	8.3
>80	3	5	9	15	0	0
Stages
Adenoma	30	50
Advanced adenoma (AA)*	30	50
I			11	18.3
IIa			17	28.3
IIb			2	3.3
IIIa			6	10
IIIb			10	16.7
IIIc			5	8.3
IV			9	15

(C) PRoBE-compliant diagnostic samples (Japanese study population)
	Cancers (n=514)		Normal controls (n=168)		Low CRC risk controls (n=159)		UC (n=59)
	n	Per cent	n	Per cent	n	Per cent	N	Per cent
Sex
Male	296	57.6	94	56	102	64.2	35	59.3
Female	218	42.4	74	44	57	35.8	24	40.7
Age (years)
<40	3	0.6	19	11.3	4	2.5	24	40.7
40–49	20	3.9	23	13.7	15	9.4	11	18.6
50–59	57	11.1	29	17.3	17	10.7	13	22
60–69	138	26.8	41	24.4	53	33.3	5	8.5
70–79	169	32.9	46	27.4	54	34	5	8.5
>80	127	24.7	10	6	16	10.1	1	1.7
Stages
I	114	22.2
37	7.2
IIa	104	20.2
IIb	10	1.9
IIc	4	0.8
III	1	0.2
IIIa	43	8.4
IIIb	77	15
IIIc	26	5.1
IV	74	14.4
Iva	10	1.9
IVb	14	2.7

*AA: see definition above.
CRC, colorectal cancer; PRoBE, prospective collection with retrospective blinded evaluation.